AI can generate 100x more drug candidates, but trials still need real patients. The bottleneck has shifted, and most sponsors ...
FDA clears Haemonetics PerQseal Elite vascular closure system for large-bore arterial procedures, showing zero major ...
UP Oncolytics secures $2.5M NIH funding to advance engineered Zika virus glioblastoma therapy toward first human trial, ...
SpyGlass Pharma's Bimatoprost Pad-IOL demonstrates four-year durability in first-in-human trial, supporting two ongoing Phase ...
Mabwell's 9MW2821 demonstrated a 30% response rate in ADC-pretreated triple-negative breast cancer patients, with an ...
Wearable devices show accuracy gaps in clinical trial endpoints, with sleep stage detection varying significantly across ...
J&J's icotrokinra hit every UC endpoint in NEJM's Oct 2026 data, and the trial design choices behind that success are ...
FDA granted four DMD antisense oligonucleotide accelerated approvals on ~1 percentage-point dystrophin increases. With $967M ...
ArriVent's firmonertinib Phase 1b data published in Cancer Cell, targeting EGFR PACC mutations resistant to standard ...
EMA's CHMP recommended 6 new medicines and 5 label expansions in its Oct 12-15 cycle. Here's what daraxonrasib's pancreatic ...
Fortrea rescued a Phase III hypercholesterolemia trial enrollment by using pre-screening logs and targeted site interventions ...
IQVIA has made Veeva CTMS, eTMF, Study Startup and Site Connect enterprise standards across its clinical development studies, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results